This trial is testing a new immunotherapy treatment for people with B-cell lymphoma that has come back or does not respond to other treatments. The new treatment consists of two drugs, nivolumab and ASTX727. Nivolumab is a monoclonal antibody that helps the body's immune system attack the cancer. ASTX727 is a combination of two drugs, decitabine and cedazuridine. Decitabine is a hypomethylation agent that helps the bone marrow produce normal blood cells. Cedazuridine is a cytidine deaminase inhibitor that prevents the breakdown of
1 Primary · 6 Secondary · Reporting Duration: Up to 2 years
Experimental Treatment
27 Total Participants · 1 Treatment Group
Primary Treatment: Decitabine and Cedazuridine · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: